10x Genomics (TXG) Short term Debt (2018 - 2019)
10x Genomics' (TXG) quarterly Short term Debt came in at $9.9 million in Q4 2019, up 136.02% year-over-year from $4.2 million in Q4 2018, and up 33.85% quarter-over-quarter from $7.4 million in Q3 2019.
Powered by 
Analysis
10x Genomics (TXG) Short term Debt (2018 - 2019) Analysis & Trends
10x Genomics has disclosed Short term Debt across 2 years of filings, most recently posting $9.9 million for Q4 2019.
- In Q4 2019, Short term Debt rose 136.02% year-over-year to $9.9 million; the TTM figure through Dec 2019 stood at $9.9 million (up 136.02% YoY), while the FY2019 annual figure was $9.9 million, up 136.02% from the prior year.
- Short term Debt came in at $9.9 million for Q4 2019 at 10x Genomics, up from $7.4 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $9.9 million in Q4 2019 to a low of $4.2 million in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 226.93 Bn | 222.99 Bn | 8.34 Bn |
| 2 | Danaher | 145.94 Bn | 141.60 Bn | 3.61 Bn |
| 3 | Agilent Technologies | 42.55 Bn | 40.79 Bn | 1.04 Bn |
| 4 | Illumina | 32.95 Bn | 31.78 Bn | 770.00 Mn |
| 5 | Revvity | 14.53 Bn | 13.51 Bn | 416.87 Mn |
| 6 | Bio-Techne | 11.31 Bn | 11.04 Bn | 211.39 Mn |
| 7 | Bio-Rad Laboratories | 10.34 Bn | 8.72 Bn | 345.80 Mn |
| 8 | Repligen | 9.46 Bn | 8.44 Bn | 110.04 Mn |
| 9 | Bruker | 8.91 Bn | 8.73 Bn | 416.00 Mn |
| 10 | 10x Genomics | 8.16 Bn | 7.61 Bn | 112.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 9.88 Mn |
| Sep 30, 2019 | 7.38 Mn |
| Dec 31, 2018 | 4.19 Mn |